FERb 033

FERb 033 is a synthetic, nonsteroidal estrogen that was synthesized in 2009 and is used in scientific research.[1][2] It is a potent and selective ERβ agonist (K_i = 7.1 nM, EC₅₀ = 4.8 nM), with 62-fold selectivity for the ERβ over the ERα.[1][2]

FERb 033

Identifiers
IUPAC name 2-Chloro-3′-fluoro-3,4′-dihydroxy-[1,1-biphenyl]-4-carboxaldehyde oxime
CAS Number	1111084-78-6
ChemSpider	24606020
UNII	9FUT9FH3EX
Chemical and physical data
Formula	C13H9ClFNO3
Molar mass	281.67 g·mol^−1
3D model (JSmol)	Interactive image
SMILES c1cc(c(cc1c2ccc(c(c2Cl)O)/C=N/O)F)O
InChI InChI=1S/C13H9ClFNO3/c14-12-9(3-1-8(6-16-19)13(12)18)7-2-4-11(17)10(15)5-7/h1-6,17-19H/b16-6+ Key:LRRMQNGSYOUANY-OMCISZLKSA-N

See also

• 8β-VE2
• Diarylpropionitrile
• ERB-196
• Erteberel
• Prinaberel
• WAY-166818
• WAY-200070
• WAY-214156

References

1. Minutolo F, Bertini S, Granchi C, Marchitiello T, Prota G, Rapposelli S, Tuccinardi T, Martinelli A, Gunther JR, Carlson KE, Katzenellenbogen JA, Macchia M (2009). "Structural evolutions of salicylaldoximes as selective agonists for estrogen receptor beta". J. Med. Chem. 52 (3): 858–67. doi:10.1021/jm801458t. PMID 19128016.
2. Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR (2014). "ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer". BMC Cancer. 14: 749. doi:10.1186/1471-2407-14-749. PMC 4196114. PMID 25288324.

External links

• FERb 033 - Tocris